Skip to main content
. 2017 Apr;361(1):140–150. doi: 10.1124/jpet.116.237701

Fig. 7.

Fig. 7.

MGCD0103 does not activate the TGF-β/SMAD pathway. (A and B) ARVFs were treated with 1 μM MGCD0103 (A) or 5 ng/ml TGF-β (B) for the indicated times prior to cell homogenization and immunoblotting with antibodies specific for PAI-1, phospho-SMAD2/3, or total SMAD2/3. Calnexin served as a loading control. Each lane represents an independent plate of cells. MGCD, MGCD0103.